These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29566213)

  • 1. Long-term persistence with rituximab in patients with rheumatoid arthritis.
    Oldroyd AGS; Symmons DPM; Sergeant JC; Kearsley-Fleet L; Watson K; Lunt M; Hyrich KL;
    Rheumatology (Oxford); 2018 Jun; 57(6):1089-1096. PubMed ID: 29566213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.
    Narongroeknawin P; Chevaisrakul P; Kasitanon N; Kitumnuaypong T; Mahakkanukrauh A; Siripaitoon B; Katchamart W;
    Int J Rheum Dis; 2018 Jan; 21(1):170-178. PubMed ID: 28737837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
    Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
    Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
    Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
    Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of bDMARD therapy in Rheumatoid Arthritis after first-line TNF-inhibitor failure: the RECORD study of the Italian Society for Rheumatology.
    Carrara G; Argnani L; Zanetti A; Zabotti A; Silvagni E; Sebastiani GD; Sebastiani M; Scirè CA
    Scand J Rheumatol; 2022 Sep; 51(5):363-367. PubMed ID: 35023421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
    Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
    Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis.
    Wilke T; Mueller S; Lee SC; Majer I; Heisen M
    BMC Musculoskelet Disord; 2017 Aug; 18(1):332. PubMed ID: 28764705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of rituximab in patients with rheumatoid arthritis: an evaluation of the UCL cohort from 1998 to 2020.
    Norris-Grey C; Cambridge G; Moore S; Reddy V; Leandro M
    Rheumatology (Oxford); 2022 Feb; 61(2):591-596. PubMed ID: 33769451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
    Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
    Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A; Wallman JK; Kristensen LE
    Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
    Łosińska K; Korkosz M; Pripp AH; Haugeberg G
    Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with long-term persistence of rituximab in rheumatoid arthritis In clinical practice: RITAR Study.
    Cañamares Orbis I; Merino Meléndez L; Llorente Cubas I; Benedí González J; García-Vicuña R; Morell Baladrón A; González-Álvaro I; Ramírez Herraiz E
    Med Clin (Barc); 2020 Jul; 155(1):1-8. PubMed ID: 31848023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
    Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
    Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.
    Chatzidionysiou K; Lie E; Lukina G; Hetland ML; Hauge EM; Pavelka K; Gabay C; Scherer A; Nordström D; Canhao H; Santos MJ; Tomsic M; Rotar Z; Hernández MV; Gomez-Reino J; Ancuta I; Kvien TK; van Vollenhoven R
    J Rheumatol; 2017 Feb; 44(2):162-169. PubMed ID: 28089978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.
    Henry J; Gottenberg JE; Rouanet S; Pavy S; Sellam J; Tubach F; Belkhir R; Mariette X; Seror R;
    Rheumatology (Oxford); 2018 Mar; 57(3):538-547. PubMed ID: 29267905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.